| ［1］ |
Yang Q, Qu L, Tian H, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis［J］. J Eur Acad Dermatol Venereol, 2011,25（12）:1409⁃1414. doi: 10.1111/ j.1468⁃3083.2011.03985.x.
|
| ［2］ |
Jo SJ, Foley P, Oakley SP, et al. Initial assessment of the early arthritis for psoriatic patients diagnostic questionnaire in dermatology clinics in Australia, Korea and China［J］. Int J Rheum Dis, 2019,22（8）:1512⁃1520. doi: 10.1111/1756⁃185X. 13604.
|
| ［3］ |
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis［J］. N Engl J Med, 2017,376（10）:957⁃970. doi: 10.1056/NEJMra150 5557.
|
| ［4］ |
Zhang A, Kurtzman D, Perez⁃Chada LM, et al. Psoriatic arthritis and the dermatologist: an approach to screening and clinical evaluation［J］. Clin Dermatol, 2018,36（4）:551⁃560. doi: 10.1016/ j.clindermatol.2018.04.011.
|
| ［5］ |
Kerschbaumer A, Fenzl KH, Erlacher L, et al. An overview of psoriatic arthritis ⁃ epidemiology, clinical features, pathophysiology and novel treatment targets［J］. Wien Klin Wochenschr, 2016,128（21⁃22）:791⁃795. doi: 10.1007/s00508⁃016⁃1111⁃9.
|
| ［6］ |
Stuart PE, Nair RP, Tsoi LC, et al. Genome⁃wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture［J］. Am J Hum Genet, 2015,97（6）:816⁃836. doi: 10.1016/j.ajhg.2015.10.019.
|
| ［7］ |
Haroon M, Winchester R, Giles JT, et al. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype［J］. Ann Rheum Dis, 2016,75（1）:155⁃162. doi: 10.1136/annrheumdis⁃2014⁃205461.
|
| ［8］ |
Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis［J］. Lancet, 2018,391（10136）:2273⁃2284. doi: 10.1016/S0140⁃6736（18）30830⁃4.
|
| ［9］ |
Shin D, Kim HJ, Kim DS, et al. Clinical features of psoriatic arthritis in Korean patients with psoriasis: a cross⁃sectional observational study of 196 patients with psoriasis using psoriatic arthritis screening questionnaires［J］. Rheumatol Int, 2016,36（2）:207⁃212. doi: 10.1007/s00296⁃015⁃3365⁃3.
|
| ［10］ |
Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis［J］. Br J Dermatol, 2014,171（5）:1123⁃1128. doi: 10. 1111/bjd.13272.
|
| ［11］ |
Klaassen KM, Ploegmakers MJ, van de Kerkhof PC, et al. Subclinical enthesitis in nail psoriasis patients: a case⁃control study［J］. J Dtsch Dermatol Ges, 2017,15（4）:405⁃412. doi: 10. 1111/ddg.13222.
|
| ［12］ |
Scriffignano S, Perrotta FM, De Socio A, et al. Role of comorbidities in spondyloarthritis including psoriatic arthritis［J］. Clin Rheumatol, 2019,38（1）:3⁃10. doi: 10.1007/s10067⁃018⁃4332⁃7.
|
| ［13］ |
Haroon M, FitzGerald O. Psoriatic arthritis: complexities, comorbidities and implications for the clinic［J］. Expert Rev Clin Immunol, 2016,12（4）:405⁃416. doi: 10.1586/1744666X. 2016.1139453.
|
| ［14］ |
Eder L, Aydin SZ. Imaging in psoriatic arthritis⁃insights about pathogenesis of the disease［J］. Curr Rheumatol Rep, 2018,20（12）:77. doi: 10.1007/s11926⁃018⁃0793⁃6.
|
| ［15］ |
Lin Z, Wang Y, Mei Y, et al. High⁃frequency ultrasound in the evaluation of psoriatic arthritis: a clinical study［J］. Am J Med Sci, 2015,350（1）:42⁃46. doi: 10.1097/MAJ.0000000000000504.
|
| ［16］ |
Kaeley GS, Eder L, Aydin SZ, et al. Enthesitis: a hallmark of psoriatic arthritis［J］. Semin Arthritis Rheum, 2018,48（1）:35⁃43. doi: 10.1016/j.semarthrit.2017.12.008.
|
| ［17］ |
Maldonado⁃Ficco H, Sheane BJ, Thavaneswaran A, et al. Magnetic resonance imaging in psoriatic arthritis: a descriptive study of indications, features and effect on treatment change［J］. J Clin Rheumatol, 2017,23（5）:243⁃245. doi: 10.1097/RHU.0000000000000558.
|
| ［18］ |
Moll JM, Wright V. Psoriatic arthritis［J］. Semin Arthritis Rheum, 1973,3（1）:55⁃78. doi: 10.1016/0049⁃0172（73）90035⁃8.
|
| ［19］ |
Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study［J］. Arthritis Rheum, 2006,54（8）:2665⁃2673. doi: 10.1002/art.21972.
|
| ［20］ |
Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis［J］. Arthritis Rheumatol, 2016,68（5）:1060⁃1071. doi: 10.1002/art.39573.
|
| ［21］ |
Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis［J］. Arthritis Rheumatol, 2019,71（1）:5⁃32. doi: 10.1002/art.40726.
|
| ［22］ |
Wilsdon TD, Whittle SL, Thynne TR, et al. Methotrexate for psoriatic arthritis［J］. Cochrane Database Syst Rev, 2019,1:CD012722. doi: 10.1002/14651858.CD012722.pub2.
|
| ［23］ |
Gisondi P, Altomare G, Ayala F, et al. Consensus on the management of patients with psoriatic arthritis in a dermatology setting［J］. J Eur Acad Dermatol Venereol, 2018,32（4）:515⁃528. doi: 10.1111/jdv.14741.
|
| ［24］ |
中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识（2019）［J］. 中华皮肤科杂志, 2019,52（12）:863⁃871. doi: 10.35541/cjd.20190892.
|
| ［25］ |
Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057.
|
| ［26］ |
McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double⁃blind, placebo⁃controlled PSUMMIT 1 trial［J］. Lancet, 2013,382（9894）:780⁃789. doi: 10.1016/S0140⁃6736（13）60594⁃2.
|
| ［27］ |
Kavanaugh A, Puig L, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo⁃controlled phase III trial［J］. Arthritis Care Res （Hoboken）, 2015,67（12）:1739⁃1749. doi: 10.1002/acr.22645.
|
| ［28］ |
van der Heijde D, Landewé RB, Mease PJ, et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis［J］. Arthritis Rheumatol, 2016,68（8）:1914⁃1921. doi: 10.1002/art.39685.
|
| ［29］ |
Coates LC, Kishimoto M, Gottlieb A, et al. Ixekizumab efficacy and safety with and without concomitant conventional disease⁃modifying antirheumatic drugs （cDMARDs） in biologic DMARD （bDMARD）⁃naïve patients with active psoriatic arthritis （PsA）: results from SPIRIT⁃P1［J/OL］. RMD Open, 2017,3（2）:e000567. doi: 10.1136/rmdopen⁃2017⁃000567.
|
| ［30］ |
Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis［J］. N Engl J Med, 2017,377（16）:1537⁃1550. doi: 10.1056/NEJMoa1615975.
|
| ［31］ |
Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors［J］. N Engl J Med, 2017,377（16）:1525⁃1536. doi: 10.1056/NEJMoa1615977.
|
| ［32］ |
Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis［J］. Rheumatology （Oxford）, 2020,59（Supplement_1）:i37⁃37i46. doi: 10.1093/rheumatology/kez383.
|
| ［33］ |
Zhao J, Di T, Wang Y, et al. Multi⁃glycoside of Tripterygium wilfordii Hook. f. ameliorates imiquimod⁃induced skin lesions through a STAT3⁃dependent mechanism involving the inhibition of Th17⁃mediated inflammatory responses［J］. Int J Mol Med, 2016,38（3）:747⁃757. doi: 10.3892/ijmm.2016.2670.
|
| ［34］ |
Zhang C, Sun PP, Guo HT, et al. Safety profiles of Tripterygium wilfordii Hook F: a systematic review and meta⁃analysis［J］. Front Pharmacol, 2016,7:402. doi: 10.3389/fphar.2016.00402.
|
| ［35］ |
Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis［J］. Ann Rheum Dis, 2015,74（6）:1045⁃1050. doi: 10.1136/annrheumdis⁃2013⁃204858.
|
| ［36］ |
Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force［J］. Ann Rheum Dis, 2018,77（1）:3⁃17. doi: 10.1136/annrheumdis⁃2017⁃211734.
|
| ［37］ |
Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis （TICOPA）: a UK multicentre, open⁃label, randomised controlled trial［J］. Lancet, 2015,386（10012）:2489⁃2498. doi: 10.1016/S0140⁃6736（15）00347⁃5.
|
| ［38］ |
Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis［J］. Ann Rheum Dis, 2010,69（8）:1441⁃1447. doi: 10.1136/ard.2009.122259.
|
| ［39］ |
戴生明, 毕新岭. 银屑病关节炎［M］. 北京: 人民卫生出版社, 2018:175⁃181.
|
| ［40］ |
Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short⁃term improvement in ankylosing spondylitis［J］. Arthritis Rheum, 2001,44（8）:1876⁃1886. doi: 10.1002/1529⁃0131（200108）44:83.0.CO;2⁃F.
|
